Format

Send to

Choose Destination
Neurol Sci. 2019 Jan;40(1):113-120. doi: 10.1007/s10072-018-3592-y. Epub 2018 Oct 12.

Vinpocetine regulates levels of circulating TLRs in Parkinson's disease patients.

Author information

1
Department of Neurology, Jiangxi Provincial People's Hospital, No, 92 Aiguo Road, Donghu District, Nanchang, 330006, Jiangxi, China. zhangkiki520@126.com.
2
Department of Neurology, Jiangxi Provincial People's Hospital, No, 92 Aiguo Road, Donghu District, Nanchang, 330006, Jiangxi, China.
3
Department of Cardiology, Jiangxi Provincial People's Hospital, No, 92 Aiguo Road, Donghu District, Nanchang, 330006, Jiangxi, China. shaoliang021224@hotmail.com.

Abstract

BACKGROUND:

The pathogenesis of Parkinson's disease (PD) is complex; it includes mitochondrial dysfunction, oxidative stress, and neuroinflammation. Notably, Toll-like receptors (TLRs) may activate inflammatory or anti-inflammatory responses in Parkinson's disease. Vinpocetine has been tested as an anti-inflammatory in both animal and in vitro research. Thus, it is important to test whether the anti-inflammatory properties of vinpocetine may have a protective effect in PD patients.

METHODS:

Eighty-nine Parkinson's disease patients and 42 healthy controls were recruited for this study. All patients were randomly assigned to either the traditional therapy group (T PD group, n = 46) or the vinpocetine group (V PD group, n = 43), in a blinded manner. Both treatments were administered for 14 days.

RESULTS:

Administration of vinpocetine reduced mRNA levels of TLR2/4, as well as protein levels of the downstream signalling molecules, MyD88 and NF-κB; moreover, it lowered the expression levels of serum inflammatory cytokines, TNF-α and MCP-1. Notably, vinpocetine increased TLR3 mRNA levels, as well as protein levels of the downstream signalling molecules TRIF-β and IRF-3, and serum levels of the anti-inflammatory cytokines IL-10 and IL-8. Furthermore, vinpocetine produced a robust increase in the Mini Mental State Examination score, compared to that achieved by using levodopa therapy.

CONCLUSION:

Vinpocetine treatment may exhibit anti-inflammatory activity and alleviate cognitive impairment.

KEYWORDS:

Neuroinflammation; Parkinson’s disease; TLRs; Vinpocetine

PMID:
30315378
DOI:
10.1007/s10072-018-3592-y
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center